# generalized anxiety disorder FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/generalized-anxiety-disorder

> 8 upcoming FDA catalysts in generalized anxiety disorder: iti-1284 10 mg (JNJ) on Mar to Jun 2027 (topline data readout); iti-1284 10 mg (JNJ) on March 2027 (primary completion); iti-1284 10 mg (JNJ) on Oct 2027 to Jan 2028 (topline data readout); iti-1284 10 mg (JNJ) on October 2027 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q1 2025 | [CYB003 topline data readout](https://sec-api.dev/pdufa/cyb003) | HELP | generalized anxiety disorder | scheduled | "Having aligned on trial design with the FDA, we recently initiated our Phase 3 PARADIGMTM pivotal program which will evaluate CYB003's efficacy and safety in a larger MDD population, and we expect to report Phase 2 topline results for CYB004, our proprietary deuterated dimethyltryptamine program for the treatment of generalized anxiety disorder, in the first quarter of 2025.1 We are committed to building on the positive clinical results to-date in both programs and to progressing CYB003 toward potential regulatory approval and commercialization," concluded Drysdale." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000106299324019233/exhibit99-1.htm)) |
| Sep 2025 | [GlyphAgo (SPT-320) trial start](https://sec-api.dev/pdufa/spt-320) | PTCHF | generalized anxiety disorder | completed | "in healthy adults for the potential treatment of generalized anxiety disorder (GAD), having announced first patient dosed in September 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782999/000119312526188811/d38199dex991.htm)) |
| Q1 2026 | [CYB004 topline data readout](https://sec-api.dev/pdufa/cyb004) | HELP | Generalized Anxiety Disorder | scheduled | "We are proud of this work to date, as well as the robust patent protection in support of our CYB004 program, and we look forward to sharing topline data in the first quarter of 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000021/a09-2025cyb004enrollmentco.htm)) |
| July 15, 2026 | [Lysergide tartrate primary completion](https://sec-api.dev/pdufa/lysergide) | DFTX | Generalized Anxiety Disorder | completed | "NCT06741228 (A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741228)) |
| August 13, 2026 | [Lysergide tartrate primary completion](https://sec-api.dev/pdufa/lysergide) | DFTX | Generalized Anxiety Disorder | completed | "NCT06809595 (A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-13 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06809595)) |
| Aug to Nov 2026 | [Lysergide tartrate topline data readout](https://sec-api.dev/pdufa/lysergide) | DFTX | Generalized Anxiety Disorder | scheduled | "NCT06809595 (A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-13 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06809595)) |
| Mar to Jun 2027 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06480383 (Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06480383)) |
| March 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06480383 (Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06480383)) |
| Oct 2027 to Jan 2028 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06701903 (Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-14 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701903)) |
| October 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06701903 (Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-14 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701903)) |
| Feb to May 2030 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07807865 (A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-18 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807865)) |
| February 2030 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07807865 (A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-18 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807865)) |
| Sep to Dec 2030 | [JNJ-99245354 topline data readout](https://sec-api.dev/pdufa/jnj-99245354) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07856420 (A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07856420)) |
| September 2030 | [JNJ-99245354 primary completion](https://sec-api.dev/pdufa/jnj-99245354) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07856420 (A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07856420)) |

## Drugs

- [CYB003](https://sec-api.dev/pdufa/cyb003) (HELP)
- [GlyphAgo (SPT-320)](https://sec-api.dev/pdufa/spt-320) (PTCHF)
- [CYB004](https://sec-api.dev/pdufa/cyb004) (HELP)
- [Lysergide tartrate](https://sec-api.dev/pdufa/lysergide) (DFTX)
- [Iti-1284 10 mg](https://sec-api.dev/pdufa/iti-1284) (JNJ)
- [JNJ-99245354](https://sec-api.dev/pdufa/jnj-99245354) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/generalized-anxiety-disorder.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "generalized anxiety disorder FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/generalized-anxiety-disorder

```bibtex
@misc{secapidev_indications_generalized_anxiety_disorder_20261116,
  title        = {generalized anxiety disorder FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/generalized-anxiety-disorder}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_generalized_anxiety_disorder_20261116","title":"generalized anxiety disorder FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/generalized-anxiety-disorder","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
